Afucosylated Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody | C103P

Catalog No.	C103P
Product Name	Afucosylated Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody | C103P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Summary	Recombinant Human IgG1 Kappa Monoclonal Antibody.
Isotype	Human IgG1 kappa.
Source/Host	The anti-SARS-CoV-2 spike monoclonal antibody sotrovimab biosimilar was produced in the sotrovimab biosimilar CHO cells.
Specificity/Sensitivity	The sotrovimab biosimilar specifically binds to the spike protein of SARS-CoV-2.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Purity	>95% by SDS-PAGE under reducing condition.
Shipping	The Afucosylated Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade sotrovimab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C103P: Afucosylated Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody
Recombinant Human IgG1 Kappa Monoclonal Antibody.

Background

What is sotrovimab biosimilar research grade? Sotrovimab is an Fc-engineered human monoclonal antibody directed against the spike protein of SARS-CoV-2. sotrovimab is a human monoclonal antibody (IgG1κ isotype). sotrovimab biosimilar uses the same protein sequences as the therapeutic antibody sotrovimab. sotrovimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, sotrovimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. sotrovimab and imdevimab bind distinct epitopes on the RBD with dissociation constants KD of 46 and 47 pM, respectively. Please contact us if you are interested in the anti-SARS-CoV-2 spike monoclonal antibody imdevimab biosimilar.

Syd Labs also provides the following research grade anti-SARS-CoV-2 spike antibody biosimilar proteins:
Casirivimab biosimilar, research grade, SARS-CoV-2 spike monoclonal antibody

Please remember our product information: Afucosylated Sotrovimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody: C103P Syd Labs

No more offers for this product!